George Clinical provides a broad range of clinical research services, including global scientific leadership, for studies into the world’s most prevalent airway diseases, including asthma and chronic obstructive pulmonary disease (COPD).
In the Asia-Pacific, asthma and COPD are particularly relevant as risk factors such as smoking, biomass fuels, pollution, and tuberculosis (TB) are higher than in other regions. Most asthma related deaths still occur in low-to-mid income countries. COPD is currently the fourth leading cause of death, expected to become the third by 2030.
COPD patients are also severely affected by co-morbidities such as heart disease and diabetes, two of George Clinical’s key areas of expertise.
Our services in respiratory health include:
Our current respiratory network encompasses:
Dr. Jenkins’ research is focused on the clinical management of airways disease and patient reported outcomes in response to therapeutic interventions. She is Head of the Respiratory Group at The George Institute for Global Health; Senior Staff Specialist in Thoracic Medicine at Concord Hospital, Sydney; Clinical Professor and Head of Respiratory Discipline at University of Sydney; and Professor of Respiratory Medicine at UNSW Sydney. She also chairs the National Asthma Campaign and the Federal Government’s National Asthma Advisory Group.
Dr. Jenkins has been Principal Investigator and has led many investigator-initiated and competitively funded clinical trials in airways disease. She is an active clinician and has had major roles in advocacy and leadership for lung health in Australia, chairing many local and international guidelines and implementation initiatives to enhance resources, skills, capacity and clinical outcomes in airways disease. She is on the Board of the Lung Foundation Australia, and is a member of the Thoracic Society of Australia and New Zealand, the American Thoracic Society, European Respirator Society and the Asia-Pacific Society of Respirology.